Resources & Guides

Patients searching for a retatrutide compounding pharmacy expect a licensed pharmacist with a white coat. The federal reality is sharper: neither 503A pharmacies nor 503B outsourcing facilities can legally produce retatrutide, because both pathways require the active ingredient to sit on an FDA-evaluated list, and retatrutide does not. This guide explains both frameworks in plain English, then traces what people actually receive when they buy from a site that calls itself a compounding pharmacy.

Tirzepatide is FDA-approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Compounded tirzepatide is a different story. Here is the full approval timeline, brand-by-brand indications, eligibility, and the compounded vs brand distinction.

Compounded tirzepatide costs a fraction of Mounjaro or Zepbound — see our full <a href="/resources/tirzepatide-cost" style="color: #2563eb;">tirzepatide cost guide</a> but sits at the center of an ongoing legal battle between Eli Lilly, compounding pharmacies, and the FDA. This guide covers the regulatory landscape after the October 2024 shortage removal, how to source safely, dosing considerations, reconstitution, storage, and what the court rulings mean for availability.

Unlike semaglutide and tirzepatide, compounded retatrutide is explicitly prohibited under federal law — there is no approved version, so the shortage exemption never applied. This guide explains the legal reality, what's actually in research-peptide vials, and what your real options are.

Compounded semaglutide costs a fraction of Ozempic or Wegovy but carries distinct risks. This guide covers the FDA regulatory landscape after the 2025 shortage resolution, how to source safely from legitimate pharmacies, dosing considerations, reconstitution, storage, and red flags to watch for.